SiRNAsense Chooses Polyplus-transfection's Delivery System
News Jun 20, 2008
siRNAsense has announced that the company has chosen to use Polyplus-transfection's "in vivo-jetPEI" delivery system for the systemic delivery of their drug candidate "siRNA targeting Tissue Factor" for treatment of melanoma metastasis. siRNAsense selected Polyplus´ delivery system after experimental validation of several potential delivery systems.
"We have chosen the Polyplus delivery system because we found it to be well suited for systemic delivery of our drug candidate against melanoma metastasis. This is a very important step for siRNAsense. Following encouraging efficacy data in a mouse model of metastasis, we are now proceeding with preclinical studies in mice and primates to further develop our drug candidate using Polyplus´ delivery system", says Hanne Mette Kristensen, CEO of siRNAsense.
siRNA is short for "small interfering RNA" and represents a major breakthrough in biology, whose potential therapeutic impact was recognized by the award of the Nobel Prize for Medicine in 2006.
siRNAsense's drug candidate is a synthetic siRNA that interferes with metastasis of melanoma, primarily by inhibiting circulating cancer cells' ability to attach to other cell membranes. For the drug to be efficient, it must be formulated in a vehicle which ensures delivery to the cancer cells. This is where Polyplus-transfection's technology has proven to be effective.
"We are delighted that siRNAsense has chosen our delivery system. We look forward to future collaboration with siRNAsense," said Joelle Bloch, CEO of Polyplus-transfection. "It is an advantage for our "in vivo-jetPEI" to be used as delivery reagent for a new therapeutic target: the treatment of melanoma metastasis."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019